Pfizer Inc.

Pfizer is a global pharmaceutical company that discovers, develops, manufactures and distributes medicines and therapeutic biological products.

Stock Performance Snapshot

Hold

Analyst Rating

Analysts suggest holding Pfizer's stock with a target price of $28.65, indicating potential growth.

Excellent

Financial Health

Pfizer is performing very well, generating strong profits, cash flow, and substantial revenue growth.

High

Dividend

Pfizer's high dividend yield of 6.87% makes it appealing for investors seeking regular income. If you invested $1000 you would be paid $68.70 a year in dividends (based on the last 12 months).

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

View more stocks by downloading the app for FREE

It only takes 60 seconds.

Baskets Featuring PFE

Healthcare Titans: Brazil Growth vs Currency Volatility

Healthcare Titans: Brazil Growth vs Currency Volatility

Brazil's healthcare sector is rapidly modernizing, creating significant demand for global innovation in areas like AI and digital health. This basket offers exposure to the US and EU-listed pharmaceutical, medical device, and technology titans that supply this growing market.

Published: October 14, 2025

Domestic Pharma Tariffs: What's Next for Investors

Domestic Pharma Tariffs: What's Next for Investors

The U.S. government has imposed a 100% tariff on pharmaceuticals from companies lacking domestic manufacturing, aiming to reshore production. This policy creates a significant advantage for U.S.-based pharmaceutical companies and their supply chains, which are poised for growth as reliance on imports decreases.

Published: September 26, 2025

Novo Nordisk Stock Risks: Healthcare Diversification

Novo Nordisk Stock Risks: Healthcare Diversification

As Africa's healthcare needs grow, demand for innovative treatments for chronic conditions like diabetes is on the rise. This basket offers potential exposure to this trend through leading global pharmaceutical and healthcare companies listed on US and EU exchanges.

Published: September 23, 2025

Johnson & Johnson (Healthcare Diversification)

Johnson & Johnson (Healthcare Diversification)

As Nigeria's population seeks stable growth opportunities, the global healthcare sector offers a compelling theme for portfolio diversification. This basket provides exposure through a collection of US and EU-listed industry leaders in pharmaceuticals, medical devices, and consumer health.

Published: September 16, 2025

Pharma Investment Basket Explained (Eli Lilly+)

Pharma Investment Basket Explained (Eli Lilly+)

Nigeria's growing population is increasingly seeking exposure to global health advancements, particularly from leading pharmaceutical innovators. This basket provides potential exposure to this trend through a collection of US and EU-listed pharmaceutical, biotechnology, and healthcare supply chain companies.

Published: September 11, 2025

Obesity Treatment (Pharma Giants vs Biotech Firms)

Obesity Treatment (Pharma Giants vs Biotech Firms)

Novo Nordisk's major restructuring, driven by intense competition from Eli Lilly, highlights the high-stakes battle in the weight-loss drug market. This theme focuses on other pharmaceutical companies that could benefit from this rivalry, either as innovators with next-generation treatments or as potential acquisition targets.

Published: September 10, 2025

Pharma's Pricing Pressure

Pharma's Pricing Pressure

In response to a presidential ultimatum for 17 drug makers to slash U.S. prices, the pharmaceutical industry faces a major regulatory challenge. This event creates a potential investment opportunity in companies positioned to gain from the pricing disruption, including generic manufacturers.

Published: August 3, 2025

Beyond The Patent Cliff: Pharma's New Growth Engines

Beyond The Patent Cliff: Pharma's New Growth Engines

AbbVie raised its profit outlook, proving it can thrive after its blockbuster Humira faced competition. This creates an investment opportunity in resilient pharmaceutical companies that are successfully launching new drugs to replace older ones.

Published: August 1, 2025

Gene Therapy's Competitive Shift

Gene Therapy's Competitive Shift

The European Medicines Agency's recent rejection of Sarepta Therapeutics' gene therapy creates a potential opening for its competitors. This theme focuses on the biopharmaceutical companies that stand to benefit from this regulatory hurdle in the Duchenne muscular dystrophy market.

Published: July 25, 2025

Next-Gen Multiple Myeloma Treatments

Next-Gen Multiple Myeloma Treatments

Discover biotech companies at the forefront of revolutionary cancer treatments. These carefully selected stocks represent innovators developing cutting-edge immunotherapies for multiple myeloma, a common blood cancer with significant unmet medical needs.

Published: July 3, 2025

The Atlantic Shift: Pharma's US Listing Trend

The Atlantic Shift: Pharma's US Listing Trend

AstraZeneca's potential move to US markets signals a growing trend among international pharmaceutical companies seeking higher valuations. This collection features global biopharma giants that could benefit from similar strategies or favorable US market dynamics.

Published: July 2, 2025

Buffett's Billions: The Philanthropy Effect

Buffett's Billions: The Philanthropy Effect

Warren Buffett just donated $6 billion to major foundations like the Gates Foundation. This curated list features companies in global health, agriculture, and education that are perfectly positioned to benefit from this massive philanthropic wave.

Published: July 1, 2025

High-Income Paycheck

High-Income Paycheck

Own a slice of established companies that pay you regularly through high dividends. These carefully selected stocks are chosen by financial experts to provide a steady stream of passive income, helping you earn money while you sleep.

Published: June 18, 2025

Market Indecision

Market Indecision

Find refuge from market volatility with these carefully selected companies providing essential goods and services. Our professional analysts have handpicked high-quality, dividend-paying stocks in defensive sectors that offer stability when economic futures look uncertain.

Published: June 18, 2025

Companies That Give Back

Companies That Give Back

Channel your investments toward companies that make philanthropy a priority. These stocks have been carefully selected by our analysts for their commitment to giving back while building sustainable businesses that could deliver long-term value to investors.

Published: June 17, 2025

Profit Sharers

Profit Sharers

These established market leaders don't just generate impressive profits—they're committed to sharing that wealth with you. Carefully selected by our analysts, these dividend powerhouses offer both reliable income streams and the stability of industry-leading businesses.

Published: June 17, 2025

Big Payout Candidates

Big Payout Candidates

This carefully selected group of companies is flush with cash and primed to reward investors. Each stock has been handpicked by our analysts for its potential to deliver exceptional returns through special dividends or substantial buybacks above their regular shareholder payouts.

Published: June 17, 2025

Most Hated Portfolio

Most Hated Portfolio

A collection of deeply undervalued stocks that have fallen out of favor with most investors. Our analysts have identified these companies as potential comeback stories with significant upside if they can navigate their current challenges.

Published: June 17, 2025

Boomer Stocks

Boomer Stocks

Discover a collection of iconic, industry-leading companies with deep market roots and reliable dividend histories. These household names have been carefully selected by our analysts for their strong brands, steady cash flow, and potential for long-term stability.

Published: June 17, 2025

7 Stocks with Dual Potential

7 Stocks with Dual Potential

This collection features companies that offer two ways to grow your money. Professional analysts predict these stocks will increase in value while also rewarding shareholders with regular dividend payments. It's like getting the best of both worlds!

Published: May 10, 2025

Pharma

Pharma

Health is wealth, and these carefully selected pharmaceutical companies could help your portfolio grow. Our professional analysts have handpicked these stocks from an industry that's projected to reach $1.9 trillion by 2027.

Published: May 6, 2025

Why You’ll Want to Watch This Stock

⚡

Pipeline and innovation

Clinical readouts and regulatory approvals can shift expectations quickly, so investors often watch the pipeline closely — though outcomes can be uncertain.

📈

Key revenue drivers

Vaccines, blockbusters and royalty agreements drive sales, but patent cliffs and pricing pressures can affect future revenue.

🌍

Global market reach

Pfizer operates worldwide with diverse market exposure, which can smooth regional volatility but also creates regulatory and geopolitical risks.

Why invest with Nemo?

🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

Eli Lilly and Company

Eli Lilly & Co is a global pharmaceutical company that develops, manufactures and markets human prescription drugs.

Johnson & Johnson

Johnson & Johnson is a multinational conglomerate pharmaceutical, medical devices, and consumer packaged goods company.

AbbVie Inc.

Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.

Frequently asked questions